Physician profile
Janet Roe
NPI 1396216560
$4,012.72
in general payments reported to CMS, 2019-2025
41 companies · $52.78 in 2025
The $52.78 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.09 · 2022: $857 · 2023: $1,755 · 2024: $1,336 · 2025: $52.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,973.05 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $620.32 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $383.20 | 2022-2024 | Keytruda, Lynparza, Lenvima |
| Celgene Corporation | $302.20 | 2022-2024 | Reblozyl, Opdualag, Pomalyst |
| Astellas Pharma US INC | $269.59 | 2023-2024 | Padcev, Xospata |
| Janssen Biotech, INC. | $213.88 | 2023-2024 | Imbruvica, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $197.64 | 2022-2024 | Enhertu, Injectafer |
| Beigene USA, INC. | $194.39 | 2022-2024 | Brukinsa |
| Seagen INC. | $178.85 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Incyte Corporation | $168.76 | 2022-2024 | Jakafi, Pemazyre, Monjuvi |
| Gilead Sciences, INC. | $161.14 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $116.19 | 2022-2024 | Opdivo, Opdualag |
| Pfizer INC. | $115.75 | 2022-2024 | |
| Coherus Oncology, INC. | $106.49 | 2022-2024 | |
| Amgen INC. | $85.40 | 2022-2023 | Blincyto |
| Glaxosmithkline, LLC. | $74.37 | 2023-2024 | Zejula |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.